EnliTIAS

ENLITISA IS A CHINESE-SWEDISH COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR INFLAMMATORY AND FIBROTIC DISEASES WITH HIGH UNMET MEDICAL NEED

Active Partnerships & Revenue Generation Since 2021

EnliTIAS

EnliTlSA: a Clinical-Stage Biotech with revenue focusing on inflammation

EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs.

EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs. 16 patent applications have been filed. Three patents have been granted respectively in China, in US and in several other territories. Now, EnliTISA is a clinical stage drug development company. The phase II clinical trial on acute respiratory distress syndrome (ARDS) has been completed in China, in March 2025; the phase Ib clinical trial on radiation-induced oral mucositis is in progress in China; and the phase I study in IPF by subcutaneous injection was completed in Sweden, in December 2024. In the future, EnliTISA could be developed into a full scale pharmaceutical company in China according to the plan of the founders. The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024. EnliTISA won the silver medal of the 13th China Innovation & Entrepreneurship Competition in 2024, which was a national competition and organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology of China.

2021

Founded in

16

International invention patents

TISA-818 ARDS SOM COPD
EnliTISA

Tel:+86-021-33758853

Add:Room 201, 202, 203, BuildingA,  Block1, No. 800, Qingdai Road, Pudong New District, Shanghai

Contact：Dr. Gu Ming

E-mail： bdservice@tisatide.com

Copyright ©2022  EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO    沪ICP备2022023966号-1  Powered by www.300.cn